about
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancerThe enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphomaComputational analysis of high-throughput flow cytometry dataSelective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoproteinCytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoproteinHuman hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Asclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression.Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cellsThe frequency and clinical relevance of multidrug resistance protein expression in patients with lymphoma.Expression of multidrug resistance 1 gene in B-cell lymphomas: association with follicular dendritic cells.Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cellsNo Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma.Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma.The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line.Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI.Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era.Prognostic value of GST-pi expression in diffuse large B-cell lymphomas.Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas.Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling.Pilot study: duodenal MDR1 and COX2 gene expression in cats with inflammatory bowel disease and low-grade alimentary lymphoma.Differential activity of P-glycoprotein in normal blood lymphocyte subsets.Challenging drug resistance in cancer therapy--review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997.
P2860
Q28378751-C6C0FF99-2D39-4EB3-B4E1-B91D8428F179Q33311418-EC8CF5C6-FD07-4890-81B9-DEFFE18BDE7DQ34307823-5D647C48-4680-4864-9F81-0CD4894C6A41Q34661616-286A4BEB-CF2D-4C5C-A9FF-EB2996E28F47Q35190691-2FB0B439-489B-4210-9D32-F21733EC5991Q35751025-0071C41A-A0E7-47EE-8A71-A884D9ED9633Q35884806-671CF6FF-3C04-4314-AC50-8A6B08D4966CQ36115251-D4493CD2-2F16-45A4-89A3-8E373511023EQ36141213-C49C6EA7-3CBD-4B2E-A402-E9354A95EB8CQ36490052-3427F6CB-6E36-42E1-BBBC-5AD41ECF3645Q37327791-002FF5B7-CA00-4BED-9EBD-567FDE3CAC1AQ37417569-51386A7C-16D7-4B98-A2DC-448E46987A47Q38756867-C029F96A-58FF-4483-BD15-8698939DF74CQ39206827-E13FA6FC-1DFA-49AD-BF27-31783B7C1AC4Q39837413-A07FF01F-9BE7-4282-B180-28773228920FQ40235799-BF8471A2-F087-4BC6-8721-5423E0629B26Q40601224-412BCF8C-9CF4-4443-8A2F-BF315E4E85FAQ40742257-08BA039E-A2F1-4E49-8162-B999CDC16F40Q42859166-D1CB3912-A9B4-4B12-9FA2-F511A7911B57Q42867439-E82FCC24-4FCF-49D8-8BBB-374A0120890CQ44443456-E4EA840A-D0A8-461B-AC8F-72948E4A5245Q45736771-FB64A916-B04B-464A-B6B4-36033F751172Q47100562-7A02EF99-9E71-41E3-9237-FA37F4A6B6B8Q47742647-C67D4480-88E0-4F98-886C-6BA9F1F70267Q47801610-A344096F-2B44-4C76-979B-71E73EE12515Q54115145-22C6E6AA-8B59-4ED1-B183-A68F39E2CE5D
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Multidrug resistance in lymphomas.
@en
Multidrug resistance in lymphomas.
@nl
type
label
Multidrug resistance in lymphomas.
@en
Multidrug resistance in lymphomas.
@nl
prefLabel
Multidrug resistance in lymphomas.
@en
Multidrug resistance in lymphomas.
@nl
P1476
Multidrug resistance in lymphomas.
@en
P2093
P304
P356
10.1200/JCO.1994.12.11.2453
P407
P577
1994-11-01T00:00:00Z